Missed PRN antihypertensive doses and inadequate glucose monitoring
Summary
Hydralazine was not administered as ordered for a resident with heart failure and hypertensive chronic kidney disease. The physician ordered hydralazine 25 mg by mouth every 12 hours as needed for hypertension when systolic blood pressure was greater than 150 mmHg, along with blood pressure monitoring every 12 hours for hydralazine use. Review of the MAR and blood pressure results showed multiple occasions when the resident’s systolic blood pressure was above 150 mmHg and the medication was not given, including readings in March, April, May, June, August, September, October, November, and December 2025. Nursing staff, the ADON, and the DON acknowledged that hydralazine should have been administered when the blood pressure met the ordered parameter. For the resident with diabetes mellitus and end stage renal disease, blood sugar monitoring was not closely managed in relation to long-acting insulin therapy. The resident had been receiving Lantus, and the record showed repeated episodes of marked hyperglycemia in January 2025, including blood glucose values over 400 mg/dL and one value of 571 mg/dL. The record also showed periods when no blood sugar monitoring was documented for extended portions of the day despite these elevated readings and ongoing insulin use. Staff stated there was no routine order for blood sugar checks from January 2025 until September 2025, even though the resident had multiple high blood sugar readings. The resident’s record further showed that blood sugar checks were being done at least three times a week before dialysis appointments, but there was no documented evidence that the resident’s elevated HgbA1c results, including 8.0 and 8.7, were addressed with evaluation of insulin therapy and blood sugar monitoring frequency. The care plan identified the resident as at risk for hypo/hyperglycemia related to diabetes and long-term insulin therapy, and the facility’s diabetes protocol stated that monitoring frequency should be adjusted based on glucose control and physician orders. The ADON stated the resident’s long-term insulin therapy should have been evaluated for the need for routine blood sugar monitoring.
Penalty
Resources
Below are regulatory guidelines relevant to this citation:
Trusted data from CMS and state health departments
Every citation, penalty and Plan of Correction is sourced from public CMS records (latest release July 29, 2026) and official state health department websites — never guesswork.
In your survey window? See what surveyors are citing.
The Survey-Prep Report maps your facility's risk from 12 months of CMS and state citation data — what's being cited around you and what to check first. $129 one-time.